HGH Frag 176-191

Mechanism

The C-terminal domain of human growth hormone reduces lipogenesis and raises lipolytic activity in adipose tissue. In obese mice and Zucker rats the fragment inhibited acetyl-CoA carboxylase and stimulated hormone-sensitive lipase in the same direction as the intact hormone, and the analogue AOD9604 did so without binding the growth hormone receptor and without inducing cell proliferation, which is the basis for the claim that the lipid action separates from the growth and glucose actions. No receptor for the fragment has been identified.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

• Reduced body-weight gain in obese rodents
• Reduced lipogenesis in adipose tissue (rodent)

Half-life, storage & sport

Elimination half-life

not on file — No pharmacokinetic study of hGH 176-191 in any species is on file. The nearest measurement is an in vitro incubation of the analogue AOD9604 in human serum and urine, which found the parent peptide less stable than its CRSVEGSCG metabolite (Drug Test Anal 2015).

Storage

not on file — no stability record on file — only research-chem retailer claims found.

In sport (WADA 2026)

Prohibited, at all times — named S2.2.3 (growth hormone fragments: hGH 176-191). the list

Reported adverse effects

No controlled human safety data exists for hGH 176-191.

• Hyperglycaemia and insulin resistance in rats given the S-carbamidomethylated 177-191 fragment (Acta Endocrinol 1982)

  Reported in one rodent studyonset: Acutereported reversible

Literature on file 9

• animal in vivo
  Reduction of cumulative body weight gain and adipose tissue mass in obese mice: response to chronic treatment with synthetic hGH 177-191 peptide (Biochem Mol Biol Int 1994;33:1011-1021) graded on: an animal model — “mice”
• animal in vivo
  Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone (Biochem Mol Biol Int 1993;30:187-196) graded on: an animal model — read from the indexed abstract — “rats”
• animal in vivo
  Effect of an antilipogenic fragment of human growth hormone on glucose transport in rat adipocytes (Biochem Mol Biol Int 1993;31:543-552) graded on: an animal model — “rat”
• animal in vivo
  Effect of C-terminal chain shortening on the insulin-antagonistic activity of human growth hormone 177-191 (Acta Endocrinol 1982;101:10-14) graded on: an animal model — read from the indexed abstract — “rats”
• animal in vivo
  Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats (J Mol Endocrinol 2000;25:287-298) graded on: an animal model — “rats”
• animal in vivo
  Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism (Am J Physiol Endocrinol Metab 2000;279:E501-7) graded on: an animal model — read from the indexed abstract — “rats”
• in vitro
  Detection and in vitro metabolism of AOD9604 (Drug Test Anal 2015;7:1-8) graded on: an in-vitro system — “in vitro”
• animal in vivo
  Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment (Int J Obes 2001;25:1442-9) graded on: an animal model — “mice”
• animal in vivo
  The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice (Endocrinology 2001;142:5182-9) graded on: an animal model — “mice”

What is circulated not evidence 4

Claims passed around in community guides and vendor copy, recorded because they circulate — not because they are true. Each is shown with the page it was read from and what this record actually holds. Checked 2026-08-24.

• unverified community data benefit ubiquitous contradicts the record

  It is circulated that clinical trials have shown Fragment 176-191 itself reduces fat mass and body weight in humans, with a positive safety profile across six trials.

  Clinical trials have shown that Fragment 176-191 administration can reduce fat mass and overall body weight

  On the record The corpus record states the published work behind the fat-loss claim is rodent, and that most of it was done on the fifteen-residue peptide hGH 177-191 or on AOD9604, a tyrosine-substituted analogue that is a different molecule. The human trials being cited were AOD9604 trials, not trials of the peptide sold as Fragment 176-191. The vendor page attributes another molecule's trials to this one.

  Source 1

• unverified community data dose ubiquitous nothing on file either way

  A dose of 200-500 mcg daily, subcutaneous, attributed to HRT clinics, circulates as the standard fat-loss protocol.

  A common HGH Fragment 176-191 dose for fat loss research based on information from HRT clinics ranges from 200-500mcg daily, subcutaneously.

  On the record The corpus holds no verified human dose for this peptide; no human dosing study of the sixteen-residue fragment is on file. The circulated range is sourced to clinic practice, not to a study.

  Source 1

• unverified community data timing common nothing on file either way

  Administration on an empty stomach, one to two times daily, is circulated as necessary because food blunts the lipolytic effect.

  HGH Fragment 176-191 is commonly administered on an empty stomach, 1-2 times daily.

  On the record Nothing on file. No study of feeding state and this fragment's activity is in the record.

  Source 1

• unverified community data benefit ubiquitous contradicts the record

  It is circulated that the fragment carries growth hormone's fat action with no negative impact on glucose handling.

  no negative impact on carbohydrate metabolism, glucose tolerance, or insulin resistance

  On the record The corpus mechanism note records that the glucose-sparing observation comes from rodent work on AOD9604, which does not bind the growth hormone receptor, and that no receptor for the fragment has been identified. The claim as circulated presents a rodent-and-analogue observation as an established human property of the traded peptide.

  Source 1

Identity

Molecular weight

1859.1

Molecular formula

C80H127N23O24S2

PubChem CID

172966176

UniProt

P01241

InChI key

OFBOQPIYGYREOZ-LWAQQTRHSA-N

Sequence

FLRIVQCRSVEGSCGF

SMILES

CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CCCNC(=N)N)CO)C(C)C)CCC(=O)O)CO)C(=O)NCC(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CC=CC=C3)N.CC(=O)O

InChI

InChI=1S/C78H123N23O22S2.C2H4O2/c1-9-42(8)62(101-68(114)47(23-17-29-86-78(83)84)91-69(115)50(30-39(2)3)95-63(109)45(79)31-43-18-12-10-13-19-43)75(121)100-61(41(6)7)74(120)94-49(24-26-56(80)104)67(113)98-55-38-125-124-37-54(65(111)88-33-57(105)89-51(76(122)123)32-44-20-14-11-15-21-44)97-70(116)52(35-102)90-58(106)34-87-64(110)48(25-27-59(107)108)93-73(119)60(40(4)5)99-71(117)53(36-103)96-66(112)46(92-72(55)118)22-16-28-85-77(81)82;1-2(3)4/h10-15,18-21,39-42,45-55,60-62,102-103H,9,16-17,22-38,79H2,1-8H3,(H2,80,104)(H,87,110)(H,88,111)(H,89,105)(H,90,106)(H,91,115)(H,92,118)(H,93,119)(H,94,120)(H,95,109)(H,96,112)(H,97,116)(H,98,113)(H,99,117)(H,100,121)(H,101,114)(H,107,108)(H,122,123)(H4,81,82,85)(H4,83,84,86);1H3,(H,3,4)/t42-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,60-,61-,62-;/m0./s1

Also called

• Fragment 176-191
• HGH Frag
• HGH Frag 176-191
• HGH Fragment 176-191

Listed prices 38

What 33 shops we track listed for HGH Frag 176-191, read from their own public catalogues on 2026-08-22. We take no commission on these and they are not ranked by any payment — how vendors are scored.